HLB Science Announces Preclinical Results of Sepsis Treatment Agent

[Asia Economy Reporter Lee Chun-hee] HLB Science announced on the 23rd that it will present the basic and preclinical research results of the sepsis treatment drug candidate 'DD-S052P' in poster form at the Korean Society for Molecular and Cellular Biology (KSMCB) conference, held from the 28th to 30th at the Jeju International Convention Center.

HLB Science is developing DD-S052P, a low-toxicity synthetic peptide with a mechanism that binds to LPS, killing bacteria and neutralizing endotoxins, as a next-generation sepsis treatment. The company explained, "According to preclinical results, in experiments using uninfected organs as controls, DD-S052P showed effects of eliminating bacteria in infected organs and lowering LPS and inflammatory cytokine levels to normal."

In July, HLB Science received approval from the French National Agency for Medicines and Health Products Safety (ANSM) for the clinical phase 1 trial plan (IND) of DD-S052P for the development of new drugs targeting sepsis and gram-negative superbug infections. The clinical trial will be conducted at Eurofins Optimed in France. Through phase 1, the company plans to verify the safety, tolerability, and pharmacokinetics of DD-S052P, a next-generation sepsis treatment that kills bacteria and neutralizes endotoxins.

Park Young-min, CEO of HLB Science, stated, "Sepsis is a serious disease causing 11 million deaths annually, with no treatment drugs available, resulting in a mortality rate of 30-50%. DD-S052P’s dual action can treat bacterial infections and sepsis caused by organ failure and other inflammatory diseases."

This content was produced with the assistance of AI translation services.